Medicine and Health

Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer

Z. Ding, Q. Li, et al.

This pilot study explores the promising safety and efficacy of the personalized neoantigen peptide-pulsed autologous dendritic cell vaccine (Neo-DCVac) for advanced lung cancer. With a well-tolerated profile and a notable objective response rate of 25%, this research could redefine treatment options for patients facing this challenging disease. Conducted by a dedicated team of researchers.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial

T. Sonoda, Y. Umeda, et al.

Medicine and Health

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

B. Besse, E. Pons-tostivint, et al.

Medicine and Health

Lymph Node Ratio Enhances Predictive Value for Treatment Outcomes in Patients with Non-Small Cell Lung Cancer Undergoing Surgery: A Retrospective Cohort Study

S. Wang, N. Mao, et al.

Medicine and Health

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

M. Yarchoan, E. J. Gane, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny